BioDelivery Sciences International, Inc. - BDSI STOCK NEWS

BioDelivery Sciences International (BDSI) reported a strong Q2 2021 with net revenue of $41.4 million, a 13% increase year-over-year, primarily driven by BELBUCA sales of $36.5 million. The company achieved a 32% EBITDA margin and GAAP net income of $9.1 million or $0.09 per share. Additionally, BDSI announced the acquisition of ELYXYB for acute migraine treatment, enhancing its portfolio in neurology. As of June 30, cash and cash equivalents were $119.9 million. Despite growth, BELBUCA's sales are expected to be at the lower end of guidance due to a slow recovery in the chronic pain market.

BioDelivery Sciences International, Inc. (BDSI) announced the acquisition of U.S. and Canadian rights to ELYXYB, a celecoxib oral solution for acute migraine treatment, from Dr. Reddy’s Laboratories. The deal involves a $6 million upfront payment and up to $9 million in additional payments. This acquisition aligns with BDSI's strategy to expand into neurology and diversify its portfolio. ELYXYB is anticipated to enhance revenue, with a cash flow positive impact expected within 24 months post-launch, slated for Q1 2022. The company also plans a pediatric study for ELYXYB to address unmet needs.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will announce its second quarter 2021 financial results on August 4, 2021, prior to market opening. A conference call will follow at 8:30 AM ET to discuss these results and provide an update on business operations. The company focuses on specialty pharmaceuticals for chronic conditions, using its proprietary BioErodible MucoAdhesive (BEMA®) technology. BDSI aims to address unmet medical needs related to chronic pain and opioid-induced constipation.

BioDelivery Sciences International (BDSI) reported Q1 2021 net revenue of $41 million, up 7% year-over-year, driven by strong BELBUCA sales of $36.4 million and Symproic sales of $4.4 million. The company achieved a net income of $5.2 million with a 22% EBITDA margin, and operating cash flow of $11 million. Despite pandemic challenges and severe weather disruptions, BELBUCA prescriptions grew by 9%. The company affirmed 2021 guidance for net sales of $170-$180 million and EBITDA of $40-$50 million.

BioDelivery Sciences International (NASDAQ: BDSI) will report its Q1 2021 financial results on May 6, 2021, prior to the U.S. market opening. A conference call will be held at 8:30 AM Eastern Time to discuss these results and business updates. BDSI specializes in developing therapies for chronic conditions, utilizing its innovative BEMA technology for effective treatment solutions. The company focuses on serious health issues like chronic pain and opioid-induced constipation.

BioDelivery Sciences International reported a 40% increase in net revenue for 2020, totaling $156.5 million, alongside a net income of $25.7 million. Key growth drivers included BELBUCA sales of $136.1 million and Symproic at $14.7 million. The fourth quarter saw revenues rise 33% to $42.2 million with a net income of $10.2 million. With a cash position of $111.6 million at year-end and optimistic 2021 guidance of $170-$180 million in sales, BDSI remains well-positioned for growth.

BioDelivery Sciences International (NASDAQ: BDSI) will report its Q4 and full-year 2020 financial results on March 10, 2021, before U.S. market open. A conference call will follow at 8:30 AM ET to discuss these results and update business operations. BDSI specializes in developing treatments for patients with chronic conditions, leveraging its proprietary BEMA® technology for chronic pain and opioid-induced constipation. Investors are encouraged to tune in for insights on the company’s performance and future outlook.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) has promoted Terry Coelho to the role of Executive Vice President and Chief Financial Officer. Coelho has served as CFO since January 2019, leading the company to profitability and enhancing its balance sheet amidst pandemic challenges. With over 30 years of finance leadership experience, she has driven key initiatives in process improvement and financial controls. CEO Jeff Bailey emphasized her importance in steering the company towards its next growth phase.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data from a Phase I safety study on BELBUCA® (buprenorphine buccal film) at the 2021 North American Neuromodulation Society Meeting (NANS) on January 16. The data compares the safety outcomes of BELBUCA® to oral oxycodone, which will be discussed in an oral presentation and related posters. The study highlights the potential benefits and safety of BELBUCA® for patients requiring opioid treatment. The posters will be available for on-demand viewing until April 16, 2021.